Skip to Main Content

Paper Details

Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Pediatr Blood Cancer
17
2020
BET, Bromodomain, I-BET726, I-BET762, MAPK, MEK, MYCN, MYCN-amplified neuroblastoma, NF1, NRAS, NRAS-mutated, RAS, extracellular signal-regulated kinase, high-risk, high-risk neuroblastoma, mitogen-activated protein kinase, neuroblastoma, neuroblastoma cell line models, neuroblastoma cell lines, non, trametinib
Author NameAffiliation
Lori S HartDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Alvin FarrelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Alvin FarrelChildren's Hospital of Philadelphia
Yimei LiDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Yimei LiPerelman School of Medicine at the University of Pennsylvania
Anastasia WyceOncology R&D, Collegeville
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
John M MarisAbramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
John M MarisAbramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania
  • 1 - 12

Datasets

Release 1.2